

Date: March 02, 2021.

To, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001.

Dear Sir,

Ref

: Script Id "BAJAJHCARE", Script Code "539872".

Sub

: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015- Update on Unit at Plot No.: N-178, MIDC

Tarapur, Boisar.

In terms of regulation 30 of SEBI (LODR) Regulations, 2015, please find attached herewith an Update on Unit at Plot No.: N-178, MIDC Tarapur, Boisar.

Kindly take the same on record.

Thanking you,

For and on behalf of Board of Directors of Bajaj Healthcare Limited

Aakash Kesari

Company Secretary

Encl: a/a



CIN: L99999MH1993PLC072892

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39A, B-39 A/1, Rd No.23, Wagle Ind. Estate Thane West – 400604.

Update on Unit at Plot No.: N-178, MIDC Tarapur, Boisar

Thane, 2nd March 2021: Bajaj Healthcare Limited (BHL) a leading manufacturer of APIs, Intermediates and Formulations, has received consent from Maharashtra Control Board (MPCB) to resume its operations at Tarapur Unit, Plot No.: N-178, MIDC Tarapur, Boisar.

Maharashtra Pollution Control Board ("MPCB") had issued a notice on 14th January, 2021 to BHL directing the closure of operations at its unit situated at Plot No. N-178, MIDC, Tarapur, Boisar – 401506 for alleged violation of the provisions of Water (Prevention and Control of Pollution) Act 1974, Air (Prevention and Control Pollution) Act 1981 and the Rules made thereunder and furtherance to our letter dated January 15, 2021.

BHL wish to update the exchange that the competent authority viz Maharashtra Pollution Control Board has vide its letter dated March 1, 2021 has given its consent to restart its manufacturing activities at the unit situated at Plot No.: N-178, MIDC Tarapur, Boisar.

About Bajaj Healthcare Limited

Bajaj Healthcare Limited a leading manufacturer of APIs, Intermediates and Formulations established in the year 1993. It specializes in manufacturing of Amino Acids, Intermediates, API, formulations & Nutraceuticals. The company has state-of-art manufacturing facilities, of which 6 units are dedicated to APIs, 2 unit to Intermediates and 1 unit for formulation. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America.

For further information on the Company, please contact:

Rupesh Nikam (CFO) **Bajaj Healthcare Limited**

Email: <u>investors@bajajhealth.com</u> Contact: +91 22 6617 7400 Vinayak Shirodkar / Krunal Shah
Captive IR Strategic Advisors Pvt. Ltd.

Email: vinayak@cap-ir.com / krunal@cap-ir.com

Contact: +91 98922 88895

Disclaimer:

CERTAIN STATEMENTS IN THIS DOCUMENT MAY BE FORWARD LOOKING STATEMENTS. SUCH FORWARD-LOOKING STATEMENTS ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES LIKE GOVERNMENT ACTIONS, LOCAL POLITICAL OR ECONOMIC DEVELOPMENTS, TECHNOLOGICAL RISKS, AND MANY OTHER FACTORS THAT COULD CAUSE OUR ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTEMPLATED BY THE RELEVANT FORWARD-LOOKING STATEMENTS. BAJAJ HEALTHCARE LTD WILL NOT BE IN ANY WAY RESPONSIBLE FOR ANY ACTION TAKEN BASED ON SUCH STATEMENTS AND UNDERTAKES NO OBLIGATION TO PUBLICLY UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT SUBSEQUENT EVENTS OR CIRCUMSTANCES.